(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 April 2014 (24.04.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/060385 A1

(51) International Patent Classification:
A61K 39/09 (2006.01) *C07K 14/315* (2006.01)

(21) International Application Number:
PCT/EP2013/071477

(22) International Filing Date:
15 October 2013 (15.10.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

1218660.7	17 October 2012 (17.10.2012)	GB
61/714,942	17 October 2012 (17.10.2012)	US
61/714,956	17 October 2012 (17.10.2012)	US
13/826,696	14 March 2013 (14.03.2013)	US
13/826,932	14 March 2013 (14.03.2013)	US
13/827,203	14 March 2013 (14.03.2013)	US

(71) Applicant: **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventor: **VERLANT, Vincent**; GlaxoSmithKline Biologicals S.A., Avenue Fleming 20, B-1300 Wavre (BE).

(74) Agents: **WHETTON, Lucy** et al.; GlaxoSmithKline, Global Patents CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: IMMUNOGENIC COMPOSITION

(57) Abstract: The present invention relates to immunogenic compositions comprising 26µg-45µg of pneumolysin and/or PhtD, vaccines comprising the immunogenic compositions and their use in medicine.

WO 2014/060385 A1